Futura Medical: Trinity Delta
2024 was a year of strategic delivery. Launch of Eroxon, an over the counter (OTC) erectile dysfunction (ED) gel, by its commercial partners in several new territories (including in the US by Haleon) enabled Futura Medical to post a maiden profit. At end-2024, Eroxon was sold in 15 countries across Europe, the Americas, and Middle East. To date, it has generated cumulative revenues of £17m for . Management is working with partners to support future launches, aiming to have Eroxon available in at least 20 markets by end-2025, and implementing commercial learnings to target Eroxon more effectively to those men most likely to benefit. Progress also continues with range extension (Eroxon Intense) and new product (WSD4000) development.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.